PE20130007A1 - Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida - Google Patents
Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamidaInfo
- Publication number
- PE20130007A1 PE20130007A1 PE2012001391A PE2012001391A PE20130007A1 PE 20130007 A1 PE20130007 A1 PE 20130007A1 PE 2012001391 A PE2012001391 A PE 2012001391A PE 2012001391 A PE2012001391 A PE 2012001391A PE 20130007 A1 PE20130007 A1 PE 20130007A1
- Authority
- PE
- Peru
- Prior art keywords
- tetrahydroisoquinolin
- methylpyrrolidin
- ethyl
- sulfonamide
- cyclohexylmethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
SE REFIERE A UN PROCESO DE PREPARACION DEL COMPUESTO 2-(CICLOHEXILMETIL)-N-{2-[(2S)-1-METILPIRROLIDIN-2-IL]ETIL}-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA QUE COMPRENDE: A) ACOPLAR (-)-2-(2-AMINOETIL)-1-METILPIRROLIDINA CON EL CLORURO DE 2-(2,2,2-TRIFLUOROACETIL)-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONILO PARA OBTENER 2-(2,2,2-TRIFLUOROACETIL)-N-{2-[(2S)-1-METILPIRROLIDIN-2-IL]ETIL}-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA EN PRESENCIA DE UNA BASE ORGANICA O INORGANICA TAL COMO HIDROXIDO DE SODIO, TRIETILAMINA, ENTRE OTROS, Y UN DISOLVENTE INERTE; B) DESPROTEGER LA 2-(2,2,2-TRIFLUOROACETIL)-N-{2-[(2S)-1-METILPIRROLIDIN-2-IL]ETIL}-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA PARA DAR N-{2-[(2S)-1-METILPIRROLIDIN-2-IL]ETIL}-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA EN CONDICIONES BASICAS Y EN UN ALCOHOL; C) AMINAR DE MANERA REDUCTORA N-{2-[(2S)-1-METILPIRROLIDIN-2-IL]ETIL}-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA CON CICLOHEXANOCARBOXALDEHIDO PARA FORMAR 2-(CICLOHEXILMETIL)-N-{2-[(2S)-1-METILPIRROLIDIN-2-IL]ETIL}-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA EN UN DISOLVENTE ORGANICO Y EN PRESENCIA DE UN AGENTE REDUCTOR TAL COMO ACIDO FORMICO; Y D) HACER REACCIONAR 2-(CICLOHEXILMETIL)-N-{2-[(2S)-1-METILPIRROLIDIN-2-IL]ETIL}-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA CON ACIDO FUMARICO PARA FORMAR EL DIFUMARATO DEL COMPUESTO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31106910P | 2010-03-05 | 2010-03-05 | |
FR1059750 | 2010-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130007A1 true PE20130007A1 (es) | 2013-02-01 |
Family
ID=44012569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012001391A PE20130007A1 (es) | 2010-03-05 | 2011-03-04 | Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida |
Country Status (27)
Country | Link |
---|---|
US (2) | US8748615B2 (es) |
EP (2) | EP2556064B1 (es) |
JP (2) | JP2013521308A (es) |
KR (2) | KR20130047685A (es) |
CN (2) | CN103221394A (es) |
AR (2) | AR080374A1 (es) |
AU (2) | AU2011223560A1 (es) |
BR (2) | BR112012022234A2 (es) |
CA (2) | CA2789669A1 (es) |
CL (2) | CL2012002452A1 (es) |
CO (2) | CO6630129A2 (es) |
CR (1) | CR20120467A (es) |
DO (1) | DOP2012000228A (es) |
EC (1) | ECSP12012207A (es) |
GT (1) | GT201200228A (es) |
IL (2) | IL221341A (es) |
MA (2) | MA34144B1 (es) |
MX (2) | MX2012008422A (es) |
NZ (2) | NZ602009A (es) |
PE (1) | PE20130007A1 (es) |
RU (2) | RU2012142338A (es) |
SG (2) | SG182576A1 (es) |
TN (1) | TN2012000361A1 (es) |
TW (2) | TW201144284A (es) |
UY (2) | UY33263A (es) |
WO (2) | WO2011109680A2 (es) |
ZA (1) | ZA201205311B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR080374A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida |
CN102816101A (zh) * | 2012-08-21 | 2012-12-12 | 江苏恒祥化工有限责任公司 | 一种(s)-n-甲基-2氯乙基吡咯烷的合成方法 |
SG11201601306QA (en) * | 2013-09-09 | 2016-03-30 | Sanofi Sa | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
WO2019070827A1 (en) * | 2017-10-04 | 2019-04-11 | Celgene Corporation | PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228170A (en) | 1979-08-30 | 1980-10-14 | Smithkline Corporation | 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds |
US4315935A (en) * | 1980-04-14 | 1982-02-16 | Smithkline Corporation | N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use |
GB8717374D0 (en) | 1987-07-22 | 1987-08-26 | Smith Kline French Lab | Pharmaceutically active compounds |
US4857301A (en) | 1987-09-25 | 1989-08-15 | Schering Corporation | Sulfonamide compounds, compositions and method of use |
WO1994029273A1 (en) | 1993-06-09 | 1994-12-22 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
GB9322976D0 (en) | 1993-11-08 | 1994-01-05 | Pfizer Ltd | Therapeutic agents |
GB9709303D0 (en) * | 1997-05-09 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
SK15072000A3 (sk) | 1998-04-10 | 2001-08-06 | Japan Tobacco Inc. | Amidové zlúčeniny |
GB9816984D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
CA2347095A1 (en) | 1998-10-16 | 2000-04-27 | Takeda Chemical Industries, Ltd. | Nitrogen-containing condensed heterocyclic derivatives, their production and agent |
NZ514144A (en) | 1999-04-01 | 2001-09-28 | Pfizer Prod Inc | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
GB9912410D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
AR025884A1 (es) | 1999-10-01 | 2002-12-18 | Takeda Pharmaceutical | Compuestos de amina ciclica, su produccion y su uso |
MXPA02005528A (es) | 1999-12-03 | 2002-09-02 | Kyoto Pharma Ind | Compuestos heterociclicos sus sales y uso medicinal. |
FR2804429B1 (fr) | 2000-01-31 | 2003-05-09 | Adir | Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2807434B1 (fr) | 2000-04-05 | 2002-10-18 | Hoechst Marion Roussel Inc | Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides |
MXPA03003397A (es) | 2000-10-20 | 2004-06-30 | Biovitrum Ab | N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia. |
ATE315023T1 (de) * | 2000-10-30 | 2006-02-15 | Warner Lambert Co | Aminoalkylpyrrolidine als serotoninrezeptorliganden sowie diese enthaltende zusammensetzungen, pharmazeutische verwendungen und methoden zu deren synthese |
AU2002254114A1 (en) | 2001-03-23 | 2002-10-08 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
CA2450856A1 (en) * | 2001-06-18 | 2002-12-27 | Maruha Corporation | Novel aliphatic compounds, their synthesis method, and utilization method of the same |
CA2456096A1 (en) | 2001-08-01 | 2003-02-13 | Mochida Pharmaceutical Co., Ltd. | Novel amine derivative having human .beta.-tryptase inhibitory activity and medecine containing the same |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
AU2002358700A1 (en) | 2001-12-26 | 2003-07-15 | Bayer Aktiengesellschaft | Urea derivatives as vr1- antagonists |
US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
JP2006523704A (ja) | 2003-04-17 | 2006-10-19 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性ヘテロサイクリックシクロペンチルテトラヒドロイソキノリンおよびテトラヒドロピリドピリジンのモジュレーター |
FR2857695B1 (fr) | 2003-07-15 | 2007-04-20 | Saint Gobain Ct Recherches | Bloc pour la filtration de particules contenues dans les gaz d'echappement d'un moteur a combustion interne |
AU2004313486A1 (en) | 2004-01-02 | 2005-07-28 | Merck & Co., Inc. | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity |
CA2553242A1 (en) | 2004-01-20 | 2005-08-04 | Merck & Co., Inc. | 2,6-disubstituted piperidines as modulators of chemokine receptor activity |
EP1742915A4 (en) | 2004-04-26 | 2009-12-02 | Merck & Co Inc | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY |
AU2005244207A1 (en) | 2004-04-26 | 2005-11-24 | Merck Sharp & Dohme Corp. | Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity |
JP2007537264A (ja) | 2004-05-11 | 2007-12-20 | インサイト コーポレイション | ケモカインレセプタのモジュレータとしての3−(4−ヘテロアリールシクロヘキシルアミノ)シクロペンタンカルボキサミド |
FR2870846B1 (fr) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
US7470722B2 (en) | 2004-06-10 | 2008-12-30 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
EP1630158A1 (en) | 2004-08-18 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
ES2257168B1 (es) | 2004-08-18 | 2007-06-01 | Laboratorios Del Dr Esteve, S.A. | Ligandos del receptor 5-ht7. |
JP4795352B2 (ja) | 2004-08-28 | 2011-10-19 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体モジュレーターとしてのピリミジンスルホンアミド誘導体 |
SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
DE602005014382D1 (de) | 2004-12-21 | 2009-06-18 | Smithkline Beecham Corp | 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren |
US20090264425A1 (en) | 2004-12-22 | 2009-10-22 | Pfizer Limited | Chemical compounds |
KR100915472B1 (ko) | 2005-01-26 | 2009-09-03 | 에프. 호프만-라 로슈 아게 | 페닐 메탄온 유도체 및 그의 글라이신 트랜스포터 1억제제로서의 용도 |
DE102005015040A1 (de) | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
AR053845A1 (es) | 2005-04-15 | 2007-05-23 | Tibotec Pharm Ltd | 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450 |
EP1891063B1 (en) | 2005-05-10 | 2012-07-25 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
EP1911747A1 (en) | 2006-10-11 | 2008-04-16 | Laboratorios del Dr. Esteve S.A. | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators |
WO2008136378A1 (ja) | 2007-04-27 | 2008-11-13 | Toyama Chemical Co., Ltd. | 新規なスルホンアミド誘導体またはその塩 |
CA2721452A1 (en) | 2008-04-16 | 2009-10-22 | Biolipox Ab | Bis-aryl compounds for use as medicaments |
US20100305173A1 (en) | 2009-04-30 | 2010-12-02 | Concert Pharmaceuticals, Inc. | Hydroxyethylamino sulfonamide derivatives |
CA2766154C (en) | 2009-06-26 | 2015-04-07 | Beverly C. Langevin | Novel fumarate salts of a histamine h3 receptor antagonist |
AR080374A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida |
-
2011
- 2011-03-03 AR ARP110100672A patent/AR080374A1/es unknown
- 2011-03-03 AR ARP110100673A patent/AR080375A1/es unknown
- 2011-03-04 PE PE2012001391A patent/PE20130007A1/es not_active Application Discontinuation
- 2011-03-04 CN CN2011800123082A patent/CN103221394A/zh active Pending
- 2011-03-04 UY UY0001033263A patent/UY33263A/es not_active Application Discontinuation
- 2011-03-04 TW TW100107248A patent/TW201144284A/zh unknown
- 2011-03-04 CN CN201180012335XA patent/CN103068815A/zh active Pending
- 2011-03-04 RU RU2012142338/04A patent/RU2012142338A/ru not_active Application Discontinuation
- 2011-03-04 SG SG2012052809A patent/SG182576A1/en unknown
- 2011-03-04 BR BR112012022234A patent/BR112012022234A2/pt not_active Application Discontinuation
- 2011-03-04 CA CA2789669A patent/CA2789669A1/en not_active Abandoned
- 2011-03-04 JP JP2012556252A patent/JP2013521308A/ja not_active Ceased
- 2011-03-04 MA MA35288A patent/MA34144B1/fr unknown
- 2011-03-04 RU RU2012142310/04A patent/RU2012142310A/ru not_active Application Discontinuation
- 2011-03-04 WO PCT/US2011/027131 patent/WO2011109680A2/en active Application Filing
- 2011-03-04 EP EP11708374.1A patent/EP2556064B1/en active Active
- 2011-03-04 MA MA35286A patent/MA34142B1/fr unknown
- 2011-03-04 NZ NZ602009A patent/NZ602009A/en not_active IP Right Cessation
- 2011-03-04 JP JP2012556254A patent/JP5927126B2/ja not_active Expired - Fee Related
- 2011-03-04 UY UY0001033262A patent/UY33262A/es not_active Application Discontinuation
- 2011-03-04 EP EP11708373A patent/EP2542530A2/en not_active Withdrawn
- 2011-03-04 NZ NZ601498A patent/NZ601498A/en not_active IP Right Cessation
- 2011-03-04 MX MX2012008422A patent/MX2012008422A/es active IP Right Grant
- 2011-03-04 CA CA2787427A patent/CA2787427C/en not_active Expired - Fee Related
- 2011-03-04 AU AU2011223560A patent/AU2011223560A1/en not_active Abandoned
- 2011-03-04 BR BR112012022356A patent/BR112012022356A2/pt not_active IP Right Cessation
- 2011-03-04 AU AU2011222588A patent/AU2011222588B2/en not_active Ceased
- 2011-03-04 SG SG2012059242A patent/SG183256A1/en unknown
- 2011-03-04 TW TW100107250A patent/TW201144285A/zh unknown
- 2011-03-04 WO PCT/US2011/027118 patent/WO2011109675A2/en active Application Filing
- 2011-03-04 MX MX2012009413A patent/MX2012009413A/es active IP Right Grant
- 2011-03-04 KR KR1020127025953A patent/KR20130047685A/ko not_active Application Discontinuation
- 2011-03-04 KR KR1020127020498A patent/KR101783679B1/ko active IP Right Grant
-
2012
- 2012-07-17 TN TNP2012000361A patent/TN2012000361A1/en unknown
- 2012-07-17 ZA ZA2012/05311A patent/ZA201205311B/en unknown
- 2012-07-19 US US13/553,455 patent/US8748615B2/en not_active Expired - Fee Related
- 2012-07-20 GT GT201200228A patent/GT201200228A/es unknown
- 2012-08-07 IL IL221341A patent/IL221341A/en not_active IP Right Cessation
- 2012-08-07 IL IL221339A patent/IL221339A0/en unknown
- 2012-08-21 DO DO2012000228A patent/DOP2012000228A/es unknown
- 2012-08-31 US US13/600,975 patent/US8779145B2/en not_active Expired - Fee Related
- 2012-09-04 CL CL2012002452A patent/CL2012002452A1/es unknown
- 2012-09-04 CL CL2012002451A patent/CL2012002451A1/es unknown
- 2012-09-13 CR CR20120467A patent/CR20120467A/es unknown
- 2012-10-02 EC ECSP12012207 patent/ECSP12012207A/es unknown
- 2012-10-04 CO CO12174778A patent/CO6630129A2/es not_active Application Discontinuation
- 2012-10-04 CO CO12174787A patent/CO6630099A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011001586A1 (es) | Metodo que comprende una composicion que contiene sulfoximida de 6-haloalquilpiridin-3-il-alquilo n-sustituida; composicion comprendiendo una mezcla estereoisomera de dicha sulfoximida en una formulacion farmaceutica acuosa. | |
AR076027A1 (es) | Metodos e intermediarios para la preparacion de agentes farmaceuticos | |
PE20160874A1 (es) | Compuestos quimicos | |
PE20140065A1 (es) | Sal(es) de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico y procesos para su elaboracion | |
CL2012001366A1 (es) | Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras. | |
UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
PE20141040A1 (es) | Composicion farmaceutica que comprende un derivado de amida que inhibe el crecimiento de celulas con cancer y lubricante de sal no metalica | |
CU24244B1 (es) | Composición farmacéutica recubierta que contiene regorafenib | |
PE20130007A1 (es) | Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida | |
CU20120137A7 (es) | Hidrato del hidrocloruro de agomelatina y preparación de éste | |
AR103230A1 (es) | Procesos para la preparación de un compuesto de diariltiohidantoína | |
CL2018000057A1 (es) | Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares | |
PE20151333A1 (es) | Composicion y usos de un ionomero antimicrobiano | |
BR112015001769A2 (pt) | Processo para a síntese de compostos de ureia substituída | |
CL2013000589A1 (es) | Metodo para preparar derivados del acido 3-amino-4-(3,4,5,5-tetrasustituido)-2-oxo-piperidin-1-il)-4-butirico por reaccion entre un acido 3,4-diaminobutanoico y un acido 5-hidroxipentanoico. | |
CO2021005258A2 (es) | Método de preparación de un compuesto de uracilo que contiene isoxazolina mediante metilación | |
CL2012000565A1 (es) | Procedimiento de preparacion del acido (+)-1,4-dihidro-7-[(3s, 4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridina-3-carboxilico (sns-595). | |
BR112012019866A8 (pt) | Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto | |
AR106195A1 (es) | Proceso para la preparación de ácido 1-(4-metanosulfonil-2-trifluorometil-bencil)-2-metil-1h-pirrolo[2,3-b]piridin-3-il-acético e intermediarios de dicha síntesis | |
AR066054A1 (es) | Proceso para preparar galantamina | |
NI201200141A (es) | Hidrato del hidrobromuro de agomelatina y preparación de éste | |
AR082593A1 (es) | Proceso para la preparacion de pirazoles | |
ES2556470T3 (es) | Procedimiento para preparar [3-[(6-cloro-3-piridinil)metil]-2-tiazolidiniliden]cianamida | |
MD4461B1 (ro) | Procedeu de sinteză a compuşilor 7,8-dimetoxi-1,3-dihidro-2H-3-benzazepin-2-onei şi aplicarea în sinteza ivabradinei | |
MA37872A1 (fr) | Sels de composé benzothiazolone utilisés en tant qu'agoniste de beta-2-adrenoceptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |